ARM partners with researchers from University of Washington to develop chips for neural implants to help people with brain and spinal injuries
Chip design giant ARM has teamed up with US researchers on a project to develop chips that can be implanted in the human brain.
Context & Ripple Effects
This 2017 partnership slots ARM into a brain-computer interface field that had already split into two camps: venture-funded vertical plays like Bryan Johnson's Kernel, which builds its own implant hardware at USC, and Musk's Neuralink, whose path since has run through FDA approval for a second implant and a planned UK clinical study for paralyzed patients.
What distinguishes ARM's move is its position: it does not run clinics or raise patient trials itself — it licenses chip architectures. Pairing with University of Washington researchers gives the medical side access to proven low-power silicon design, while the broader BCI effort, including DARPA's 64,000-electrode array program shows how much compute ambition the field carries.
First-order effects
- University of Washington's implant project gains ARM's low-power chip design expertise directly, letting the research team prototype implantable processors without standing up its own silicon design operation.
- ARM opens a new licensing surface beyond phones and embedded devices: if the collaboration produces usable implant chip designs, ARM can collect royalties as other BCI teams adopt them.
Second-order effects
- Vertically integrated rivals like Kernel and Neuralink face a potential commoditization threat — if ARM-standard implant silicon becomes available, their proprietary-chip moat narrows to surgical technique and software rather than the processor itself.
- Medical-device component suppliers gain a reference architecture for implants, lowering the barrier for smaller research hospitals and startups to enter trials that previously required custom chip programs.
Third-order effects
- If licensed, standards-based silicon becomes the default for implants, the industry restructures the way mobile did: ARM-style architecture owners capture value across many device makers, while differentiation migrates to electrodes, biocompatibility, and clinical validation.
- Regulators such as the FDA, already exercised by Neuralink's approvals, would face a stream of implant submissions built on common chip platforms — pushing toward standardized evaluation criteria for neural hardware.
The trend: Chip architecture firms are extending ultra-low-power silicon licensing from phones into implanted medical devices, positioning themselves as suppliers to a BCI field currently led by vertically integrated startups.